Publication & Citation Trends
Publications
0 total
P871: ISB 1442, A FIRST-IN-CLASS CD38 AND CD47 BISPECIFIC ANTIBODY INNATE CELL MODULATOR FOR THE TREATMENT OF CD38 POSITIVE HEMATOLOGICAL MALIGNANCIES OA
Cited by 1
Semantic Scholar
Preclinical Evaluation of ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of AML and T-ALL OA
Cited by 5
Semantic Scholar
Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy
Cited by 43
Semantic Scholar
Correction to: Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy OA
Cited by 1
Semantic Scholar
Abstract 18: MMP9 inhibition in mouse models of breast cancer: Therapeutic synergy with vinorelbine-based chemotherapy
Cited by 2
Semantic Scholar
Abstract 1017: Vinorelbine, cyclophosphamide, and 5-FU effects on the circulating and intratumoral landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma
Cited by 0
Semantic Scholar
Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma OA
Cited by 89
Semantic Scholar
Abstract 5919: Identification of a novel molecular interaction, targeted by Metformin, between breast cancer and white adipose tissue progenitors OA
Cited by 1
Semantic Scholar
Research Topics
Cancer Cells and Metastasis
(11)
Cancer Immunotherapy and Biomarkers
(8)
RNA modifications and cancer
(6)
Metabolism, Diabetes, and Cancer
(5)
Immune cells in cancer
(4)
Affiliations
Glenmark Pharmaceuticals (Switzerland)
Ripamonti
European Institute of Oncology